Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KEVIN L WINTHROP

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1679509525
CMS profile
257855
Location
PORTLAND, OR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$202,684.68

59 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $56,924.35 13
ABBVIE INC. $55,575.00 16
UCB SA $45,005.00 5
Roche Products Limited $11,650.00 3
BioMarin Pharmaceutical Inc. $5,850.00 3
E.R. Squibb & Sons, L.L.C. $5,400.00 2
Janssen Research & Development, LLC $4,825.00 1
Fresenius Kabi USA, LLC $3,960.00 1
Novartis Pharma AG $3,900.00 3
Zambon USA Ltd. $3,000.00 1
Insmed, Inc. $2,864.52 7
PFIZER INC. $1,625.00 1
GlaxoSmithKline, LLC. $1,505.81 2
Celgene Corporation $600.00 1

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KEVIN L WINTHROP

NPI 1679509525 · CMS profile ID 257855

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

PORTLAND, OR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679509525?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KEVIN L WINTHROP, NPI 1679509525, CMS profile ID 257855. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679509525?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). KEVIN L WINTHROP, NPI 1679509525, CMS profile ID 257855. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679509525?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
KEVIN L WINTHROP, NPI 1679509525, CMS profile ID 257855, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1679509525?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

59 matching records · $202,684.68 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 59 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–59 of 59.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $1,398.6802/18/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944950521 CMS
BioMarin Pharmaceutical Inc. $2,250.0002/04/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929751479 CMS
BioMarin Pharmaceutical Inc. $1,350.0002/04/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929751487 CMS
Fresenius Kabi USA, LLC $3,960.0002/01/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 961072379 CMS
Insmed, Inc. $1,625.0002/01/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 906438467 CMS
ABBVIE INC. $3,900.0001/21/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892657077 CMS
E.R. Squibb & Sons, L.L.C. $4,800.0001/20/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932651821 CMS
Eli Lilly and Company $12,000.0001/18/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918105573 CMS
Eli Lilly and Company $34,450.0001/04/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918123629 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $171,709.30 114
PY2020 $258,659.24 63
PY2021 $230,514.78 61
PY2022 $202,684.68 59
PY2023 $258,852.38 98
PY2024 $415,021.28 110
PY2025 $289,193.56 75

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $261,368.75 33
PY2025 Principal investigator $403,130.29 72
PY2024 Recipient $111,717.50 32
PY2024 Principal investigator $1,484,791.73 279
PY2023 Recipient $105,412.50 27
PY2023 Principal investigator $394,404.53 166
PY2022 Recipient $100,399.00 28
PY2022 Principal investigator $3,202,007.70 149
PY2021 Recipient $136,983.81 32
PY2021 Principal investigator $1,496,429.40 79
PY2020 Recipient $224,120.28 49
PY2020 Principal investigator $46,760.48 13
PY2019 Recipient $39,252.50 11
PY2019 Principal investigator $118,643.36 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

105 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Takeda Pharmaceuticals U.S.A., Inc. $4,615.00 12/31/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223263366
Recipient PFIZER INC. $3,200.00 12/19/2025 Covered Recipient Physician TOFACITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727349
Recipient Genentech, Inc. $5,200.00 12/16/2025 Covered Recipient Physician Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1211537121
Principal investigator 1 bioMerieux Inc $75,273.76 12/16/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489157
Principal investigator 1 bioMerieux Inc $27,100.40 12/16/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489159
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $39,236.00 12/11/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
RD007067 No dispute reported 06/30/2026 1244347121
Recipient Genentech, Inc. $3,575.00 12/05/2025 Covered Recipient Physician Gazyva for the treatment of MN No dispute reported 06/30/2026 1211537138
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $710.00 12/01/2025 Covered Recipient Physician PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH ACTIVE PRIMARY SJGRENS SYNDROME (PSS) No dispute reported 06/30/2026 1225334751
Recipient ABBVIE INC. $7,631.25 11/20/2025 Covered Recipient Physician A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202402440
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $78,383.75 10/28/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
The immunogenicity and safety of Zostavax in rheumatoid arthritis patients using biologic therapy No dispute reported 06/30/2026 1236000414
Recipient Genentech, Inc. $4,615.00 10/21/2025 Covered Recipient Physician Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN No dispute reported 06/30/2026 1211537118
Recipient ABBVIE INC. $4,537.50 10/09/2025 Covered Recipient Physician A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202402436
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $2,130.00 10/08/2025 Covered Recipient Physician PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH ACTIVE PRIMARY SJGRENS SYNDROME (PSS) No dispute reported 06/30/2026 1225334749
Principal investigator 1 Verona Pharma, Inc. $16,753.94 10/03/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Verona No dispute reported 06/30/2026 1232892215
Recipient Takeda Pharmaceuticals U.S.A., Inc. $5,325.00 09/25/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223263364
Principal investigator 1 Roche Diagnostics Operations, Inc. $54.60 09/24/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
RD007067 No dispute reported 06/30/2026 1186331195
Principal investigator 1 Roche Diagnostics Operations, Inc. $27.22 09/18/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
RD007067 No dispute reported 06/30/2026 1186331305
Principal investigator 1 bioMerieux Inc $31,350.00 09/16/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489153
Principal investigator 1 bioMerieux Inc $29,929.00 09/16/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489155
Recipient Takeda Pharmaceuticals U.S.A., Inc. $4,400.00 09/15/2025 Covered Recipient Physician A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223263362
Principal investigator 1 Roche Diagnostics Operations, Inc. $8,640.20 09/07/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
RD007067 No dispute reported 06/30/2026 1186331281
Principal investigator 1 Roche Diagnostics Operations, Inc. $496.13 09/04/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
RD007067 No dispute reported 06/30/2026 1186331241
Recipient Takeda Pharmaceuticals U.S.A., Inc. $3,905.00 08/29/2025 Covered Recipient Physician A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223263360
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $4,970.00 08/13/2025 Covered Recipient Physician PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH ACTIVE PRIMARY SJGRENS SYNDROME (PSS) No dispute reported 06/30/2026 1225334747
Principal investigator 1 bioMerieux Inc $1,590.56 07/23/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489167
Principal investigator 1 bioMerieux Inc $33.66 07/23/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489201
Principal investigator 1 Verona Pharma, Inc. $2,904.08 06/18/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Verona No dispute reported 06/30/2026 1232892076
Recipient NS Pharma, Inc. $7,100.00 06/13/2025 Covered Recipient Physician Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis No dispute reported 06/30/2026 1242700174
Recipient Takeda Pharmaceuticals U.S.A., Inc. $3,550.00 05/16/2025 Covered Recipient Physician A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223263358
Principal investigator 1 Verona Pharma, Inc. $8,604.72 04/25/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Verona No dispute reported 06/30/2026 1232892074
Principal investigator 1 bioMerieux Inc $19.32 04/25/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489161
Principal investigator 1 bioMerieux Inc $2.74 04/25/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489163
Principal investigator 1 bioMerieux Inc $695.87 04/25/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489165
Principal investigator 1 bioMerieux Inc $41.58 04/25/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489169
Principal investigator 1 bioMerieux Inc $1,288.98 04/25/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489171
Principal investigator 1 bioMerieux Inc $396.58 04/25/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489173
Principal investigator 1 bioMerieux Inc $16.00 04/25/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489175
Principal investigator 1 bioMerieux Inc $254.06 04/25/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489177
Principal investigator 1 bioMerieux Inc $977.20 04/25/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489179
Principal investigator 1 bioMerieux Inc $33.66 04/25/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489181
Principal investigator 1 bioMerieux Inc $80.53 04/25/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489183
Principal investigator 1 bioMerieux Inc $35.22 04/25/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489185
Principal investigator 1 bioMerieux Inc $50.90 04/25/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489187
Principal investigator 1 bioMerieux Inc $53.42 04/25/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489189
Principal investigator 1 bioMerieux Inc $270.14 04/25/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489191
Principal investigator 1 bioMerieux Inc $919.38 04/25/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489193
Principal investigator 1 bioMerieux Inc $63.60 04/25/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489195
Principal investigator 1 bioMerieux Inc $13.94 04/25/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489197
Principal investigator 1 bioMerieux Inc $29.95 04/25/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Performance Evaluation of the VIDAS TB-IGRA Assay No dispute reported 06/30/2026 1253489199
Recipient Bausch Health US, LLC $5,500.00 04/11/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224834969
Recipient Bausch Health US, LLC $7,500.00 04/11/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224834973
Recipient Bausch Health US, LLC $3,500.00 04/11/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224834977
Recipient Bausch Health US, LLC $650.00 04/11/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224834981
Recipient Bausch Health US, LLC $7,500.00 04/11/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224834986
Principal investigator 1 Verona Pharma, Inc. $20,615.76 03/26/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
Verona No dispute reported 06/30/2026 1232892054
Recipient Regeneron Pharmaceuticals, Inc. $4,000.00 03/20/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184123952
Recipient E.R. Squibb & Sons, L.L.C. $100,465.00 03/18/2025 Covered Recipient Physician A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis Who Are Nave to Biologic Disease-modifying Anti-rheumatic Drugs No dispute reported 06/30/2026 1242720071
Recipient Takeda Pharmaceuticals U.S.A., Inc. $3,550.00 03/03/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223263356
Principal investigator 1 Insmed, Inc. $205.70 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646366
Principal investigator 1 Insmed, Inc. $850.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646470
Principal investigator 1 Insmed, Inc. $300.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646472
Principal investigator 1 Insmed, Inc. $300.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646474
Principal investigator 1 Insmed, Inc. $850.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646476
Principal investigator 1 Insmed, Inc. $2,200.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646478
Principal investigator 1 Insmed, Inc. $650.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646480
Principal investigator 1 Insmed, Inc. $1,280.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646482
Principal investigator 1 Insmed, Inc. $320.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646484
Principal investigator 1 Insmed, Inc. $300.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646486
Principal investigator 1 Insmed, Inc. $677.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646488
Principal investigator 1 Insmed, Inc. $850.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646490
Principal investigator 1 Insmed, Inc. $2,200.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646492
Principal investigator 1 Insmed, Inc. $850.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646494
Principal investigator 1 Insmed, Inc. $850.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646496
Principal investigator 1 Insmed, Inc. $850.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646498
Principal investigator 1 Insmed, Inc. $850.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646500
Principal investigator 1 Insmed, Inc. $850.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646502
Principal investigator 1 Insmed, Inc. $2,200.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646504
Principal investigator 1 Insmed, Inc. $300.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646506
Principal investigator 1 Insmed, Inc. $25.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646508
Principal investigator 1 Insmed, Inc. $650.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646510
Principal investigator 1 Insmed, Inc. $25.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646512
Principal investigator 1 Insmed, Inc. $550.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646514
Principal investigator 1 Insmed, Inc. $850.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646516
Principal investigator 1 Insmed, Inc. $200.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646518
Principal investigator 1 Insmed, Inc. $500.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646520
Principal investigator 1 Insmed, Inc. $300.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646522
Principal investigator 1 Insmed, Inc. $800.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646524
Principal investigator 1 Insmed, Inc. $25.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646526
Principal investigator 1 Insmed, Inc. $25.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646528
Principal investigator 1 Insmed, Inc. $600.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646530
Principal investigator 1 Insmed, Inc. $25.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646532
Principal investigator 1 Insmed, Inc. $450.00 02/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646534
Recipient E.R. Squibb & Sons, L.L.C. $25,560.00 02/18/2025 Covered Recipient Physician Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1236001919
Principal investigator 1 Paratek Pharmaceuticals, Inc. $5,620.00 02/13/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex No dispute reported 06/30/2026 1181710972
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,380.00 02/05/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185543174
Recipient Bausch Health US, LLC $4,500.00 01/24/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224834948
Recipient Bausch Health US, LLC $8,000.00 01/24/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224834953
Recipient Bausch Health US, LLC $3,500.00 01/24/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224834957
Recipient Bausch Health US, LLC $2,500.00 01/24/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224834961
Recipient Bausch Health US, LLC $7,000.00 01/24/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224834965
Recipient Genentech, Inc. $2,600.00 01/23/2025 Covered Recipient Physician Gazyva for the treatment of MN No dispute reported 06/30/2026 1211537130
Recipient Genentech, Inc. $2,840.00 01/21/2025 Covered Recipient Physician Study to investigate safety and efficiacy of Obinutuzumab in Patients with SLE No dispute reported 06/30/2026 1211537126
Recipient Genentech, Inc. $3,900.00 01/21/2025 Covered Recipient Physician Study to investigate safety and efficiacy of Obinutuzumab in Patients with SLE No dispute reported 06/30/2026 1211537134
Recipient Takeda Pharmaceuticals U.S.A., Inc. $2,840.00 01/16/2025 Covered Recipient Physician A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223263354
Principal investigator 1 Paratek Pharmaceuticals, Inc. $22,135.74 01/09/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex No dispute reported 06/30/2026 1181710970